Safety issues that led to the withdrawals of the cannabinoid receptor antagonist Acomplia (rimonabant) and, before that, appetite suppressant Redux (dexfenfluramine), mean that novel products are ...
1, 1; 2008). Two major drugs that analysts had previously expected to be launched in 2007, Acomplia (rimonabant; Sanofi–Aventis) for obesity and Galvus (vildagliptin; Novartis) for type 2 ...
Sanofi's Acomplia, which never won U.S. approval, was withdrawn in Europe in 2008 after being linked to suicidal thoughts. The weight-loss drug Contrave carries a black box warning about suicidal ...
Shares of the Paris-based drug giant have fallen about 9% since July 2006 because of concerns about generic competition and delays in the launch of its anti-obesity product, Acomplia. But a rich ...